JP4149803B2 - 組成物の調製方法 - Google Patents

組成物の調製方法 Download PDF

Info

Publication number
JP4149803B2
JP4149803B2 JP2002504983A JP2002504983A JP4149803B2 JP 4149803 B2 JP4149803 B2 JP 4149803B2 JP 2002504983 A JP2002504983 A JP 2002504983A JP 2002504983 A JP2002504983 A JP 2002504983A JP 4149803 B2 JP4149803 B2 JP 4149803B2
Authority
JP
Japan
Prior art keywords
weight
dispersion
solution
composition
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002504983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501184A5 (https=
JP2004501184A (ja
Inventor
ブソーン,パトリック
シュローダー,マルコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4149803(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004501184A publication Critical patent/JP2004501184A/ja
Publication of JP2004501184A5 publication Critical patent/JP2004501184A5/ja
Application granted granted Critical
Publication of JP4149803B2 publication Critical patent/JP4149803B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002504983A 2000-06-27 2001-06-18 組成物の調製方法 Expired - Lifetime JP4149803B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113535 2000-06-27
PCT/EP2001/006834 WO2002000201A2 (en) 2000-06-27 2001-06-18 Method for preparing a composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007180722A Division JP2007302683A (ja) 2000-06-27 2007-07-10 組成物の調製方法

Publications (3)

Publication Number Publication Date
JP2004501184A JP2004501184A (ja) 2004-01-15
JP2004501184A5 JP2004501184A5 (https=) 2005-02-03
JP4149803B2 true JP4149803B2 (ja) 2008-09-17

Family

ID=8169074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002504983A Expired - Lifetime JP4149803B2 (ja) 2000-06-27 2001-06-18 組成物の調製方法
JP2007180722A Pending JP2007302683A (ja) 2000-06-27 2007-07-10 組成物の調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007180722A Pending JP2007302683A (ja) 2000-06-27 2007-07-10 組成物の調製方法

Country Status (37)

Country Link
US (3) US6534087B2 (https=)
EP (1) EP1296656B1 (https=)
JP (2) JP4149803B2 (https=)
KR (1) KR100557845B1 (https=)
CN (1) CN1236764C (https=)
AR (1) AR029278A1 (https=)
AT (1) ATE334662T1 (https=)
AU (2) AU8184601A (https=)
BR (1) BRPI0112014B1 (https=)
CA (1) CA2411153C (https=)
CY (1) CY1105714T1 (https=)
CZ (1) CZ301813B6 (https=)
DE (1) DE60121953T2 (https=)
DK (1) DK1296656T3 (https=)
EC (1) ECSP024401A (https=)
EG (1) EG24141A (https=)
ES (1) ES2269441T3 (https=)
HR (1) HRP20021009B1 (https=)
HU (1) HU229550B1 (https=)
IL (2) IL153282A0 (https=)
JO (1) JO2247B1 (https=)
MA (1) MA26922A1 (https=)
ME (1) ME00672B (https=)
MX (1) MXPA02012583A (https=)
MY (1) MY129798A (https=)
NO (1) NO332181B1 (https=)
NZ (1) NZ523024A (https=)
PE (1) PE20020101A1 (https=)
PL (1) PL203804B1 (https=)
PT (1) PT1296656E (https=)
RU (1) RU2244542C2 (https=)
SI (1) SI1296656T1 (https=)
TW (1) TWI278325B (https=)
UY (1) UY26799A1 (https=)
WO (1) WO2002000201A2 (https=)
YU (1) YU96602A (https=)
ZA (1) ZA200209649B (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
PL203804B1 (pl) * 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
KR100625399B1 (ko) * 2002-04-26 2006-09-20 에프. 호프만-라 로슈 아게 리파아제 억제제 및 글루코마난을 포함하는 약학 조성물
KR100517072B1 (ko) * 2002-11-25 2005-09-26 주식회사 태평양 폴리올/고분자 마이크로캡슐 및 이를 이용한 효소 안정화방법
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
CA2548892C (en) * 2003-12-12 2015-10-27 Eran Eilat Compositions for treatment of ear disorders and methods of use thereof
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
EP1737405A2 (en) * 2004-04-06 2007-01-03 RPG Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
JP4329816B2 (ja) * 2004-09-15 2009-09-09 萬有製薬株式会社 サンプリング方法、サンプリング装置、logD測定方法及びlogD測定システム
EP2163196A3 (en) * 2004-12-31 2010-11-03 Mikhail Yurievich Gotovsky Device for measuring the presence of foreign substances in a living organism and for individually selecting preparations for increasing an organism's life activity
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
US20070060610A1 (en) * 2005-06-16 2007-03-15 Wempe Michael F Methods and pharmaceutical formulations for increasing bioavailability
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
EP1987825B1 (en) 2006-02-20 2018-09-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
JP2009530614A (ja) 2006-03-16 2009-08-27 デューク ユニバーシティ フーリエ領域光コヒーレンス・トモグラフィーに基づく実時間直角位相投影を実行するための方法、システム及びコンピュータプログラム製品
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (ko) 2006-09-27 2008-03-12 주식회사 제닉 키토산과 폴리에틸렌글리콜을 이용한 생체친화성 저독성필름
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
AU2008254748A1 (en) * 2007-05-18 2008-11-27 Tti Ellebeau, Inc. Transdermal delivery devices assuring an improved release of an active principle through a biological interface
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2435554B1 (en) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
AU2010301135A1 (en) * 2009-09-29 2012-04-12 Michael Burnet Novel pesticide formulations
KR100940745B1 (ko) * 2009-10-15 2010-02-04 광동제약 주식회사 오를리스타트 및 아타풀지트 함유 복합제의 코팅펠렛 및 이를 이용한 제제
PL2529004T3 (pl) 2010-01-28 2017-12-29 Advanced Bionutrition Corporation Sucha szklista kompozycja zawierająca bioaktywny materiał
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101021030B1 (ko) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 형광체 코팅방법, 발광장치 제조방법 및 코팅된 형광체
DK2557151T3 (en) * 2010-04-07 2017-12-11 Mitsubishi Gas Chemical Co S-adenosyl-L-methionine-containing dry yeast composition with excellent storage stability and process for preparing the same
AR082682A1 (es) 2010-08-13 2012-12-26 Advanced Bionutrition Corp Composicion estabilizadora de almacenamiento en seco para materiales biologicos
AU2011320159B2 (en) 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
EP2680815B1 (en) 2011-03-01 2016-08-17 The Procter and Gamble Company Porous disintegratable solid substrate for personal health care applications
MX356072B (es) 2012-03-23 2018-05-14 Advanced Bionutrition Corp Composicion estabilizante para materiales biologicos.
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
PY1639434A (es) 2015-06-25 2018-08-01 Ascus Biosciences Inc Procedimientos, aparatos y sistemas para el analisis de cepas de microorganismos provinientes de comunidades complejas y heterogenas. prediccion e identificacion de relaciones..//.
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
CA3048246A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
AU2017388535A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
ATE216577T1 (de) 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
WO1994018951A1 (en) * 1993-02-23 1994-09-01 Warner-Lambert Company A process for the preparation of substantially alcohol free pharmaceutical compositions
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
CN100409844C (zh) 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
CN103772231B (zh) 1995-02-27 2016-02-03 吉里德科学公司 新颖化合物,其合成方法及治疗用途
DE69628007T2 (de) * 1995-06-07 2003-11-27 Elan Drug Delivery Ltd., Ruddington Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
ES2217410T3 (es) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. Forma de dosificacion oral de rapida desintegracion.
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (ja) 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
AU3705799A (en) * 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
PL203804B1 (pl) * 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem

Also Published As

Publication number Publication date
YU96602A (sh) 2005-03-15
ZA200209649B (en) 2004-03-10
EG24141A (en) 2008-08-06
MEP90608A (bs) 2011-12-20
UY26799A1 (es) 2001-12-28
HRP20021009A2 (en) 2004-02-29
KR20030023880A (ko) 2003-03-20
MXPA02012583A (es) 2003-04-10
HK1058314A1 (en) 2004-05-14
BRPI0112014B1 (pt) 2016-09-13
AU2001281846B2 (en) 2006-04-27
NO332181B1 (no) 2012-07-16
CA2411153C (en) 2007-01-30
CN1438880A (zh) 2003-08-27
PE20020101A1 (es) 2002-02-12
WO2002000201A3 (en) 2002-04-18
BR0112014A (pt) 2003-05-13
ME00672B (me) 2011-12-20
IL153282A (en) 2008-03-20
CY1105714T1 (el) 2010-12-22
JO2247B1 (en) 2004-10-07
TWI278325B (en) 2007-04-11
SI1296656T1 (sl) 2006-12-31
RU2244542C2 (ru) 2005-01-20
JP2007302683A (ja) 2007-11-22
CN1236764C (zh) 2006-01-18
ECSP024401A (es) 2003-02-06
NO20026197D0 (no) 2002-12-23
US7074431B2 (en) 2006-07-11
WO2002000201A2 (en) 2002-01-03
PL203804B1 (pl) 2009-11-30
NO20026197L (no) 2002-12-23
US20020018812A1 (en) 2002-02-14
US6534087B2 (en) 2003-03-18
IL153282A0 (en) 2003-07-06
PL365803A1 (en) 2005-01-10
US20030039614A1 (en) 2003-02-27
PT1296656E (pt) 2006-12-29
HUP0302060A3 (en) 2006-07-28
HRP20021009B1 (hr) 2011-07-31
CZ301813B6 (cs) 2010-06-30
HU229550B1 (en) 2014-01-28
ES2269441T3 (es) 2007-04-01
CZ2003212A3 (cs) 2003-06-18
KR100557845B1 (ko) 2006-03-10
MA26922A1 (fr) 2004-12-20
US20060134205A1 (en) 2006-06-22
MY129798A (en) 2007-04-30
ATE334662T1 (de) 2006-08-15
AU8184601A (en) 2002-01-08
AR029278A1 (es) 2003-06-18
DK1296656T3 (da) 2006-11-27
DE60121953T2 (de) 2007-03-08
EP1296656B1 (en) 2006-08-02
NZ523024A (en) 2004-08-27
HUP0302060A2 (hu) 2003-09-29
EP1296656A2 (en) 2003-04-02
DE60121953D1 (de) 2006-09-14
JP2004501184A (ja) 2004-01-15
CA2411153A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
JP4149803B2 (ja) 組成物の調製方法
AU2001281846A1 (en) Method for preparing a composition
Jatwani et al. An overview on solubility enhancement techniques for poorly soluble drugs and solid dispersion as an eminent strategic approach
CN101193624B (zh) 通过短期加热和快速干燥制备基于不良水溶性的活性物质的固溶体
JP2018535943A (ja) 輸液又は注射として及び輸液濃縮物の静脈内投与のためのレボシメンダンの改善された調製物
Yusuf et al. Effect of cellulose derivative matrix and oligosaccharide on the solid state and physical characteristics of dimethyldioctadecylammoniumliposomes for vaccine
Nugraheni et al. Freeze-dried liposome formulation for small molecules, nucleic acid, and protein delivery
EP1432406B1 (en) Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support
Juan-Juan et al. Improved stability and oral bioavailability of Ganneng dropping pills following transforming lignans of herpetospermum caudigerum into nanosuspensions
HK1058314B (en) Method for preparing a composition
Bhura et al. Poorly water-soluble drugs and formulation strategy to improve oral bioavailability
Muthukumar Chapter-6 Solid Dispersion
EP4719401A2 (en) Stable solid oral formulation of tafamidis or pharmaceutically acceptable salt thereof
Peterson et al. Lipid and amino acid shell formers as aerosolization-and stability-enhancers in spray-dried high-dose amorphous drug product
JP2006306740A (ja) 固形状医薬組成物及びその製造方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070710

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080624

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080626

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110704

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4149803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110704

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120704

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130704

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term